A Comprehensive Review About SARS-CoV-2

Overview

Journal Future Virol

Specialty Microbiology

Date 2020 Nov 23

PMID 33224265

Citations 35

Authors

Sk Manirul Haque

Omar Ashwaq

Abdulla Sarief

Abdul Kalam Azad John Mohamed

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease (COVID-19) was first identified in China, December 2019. Since then, it has spread the length and breadth of the world at an unprecedented, alarming rate. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which causes COVID-19, has much in common with its closest homologs, SARS-CoV and Middle East respiratory syndrome-CoV. The virus-host interaction of SARS-CoV-2 uses the same receptor, ACE2, which is similar to that of SARS-CoV, which spreads through the respiratory tract. Patients with COVID-19 report symptoms including mild-to-severe fever, cough and fatigue; very few patients report gastrointestinal infections. There are no specific antiviral strategies. A few strong medications are under investigation, so we have to focus on proposals which ought to be taken to forestall this infection in a living host.

Citing Articles

Lactoferrin Binds through Its N-Terminus to the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.

Babulic P, Cehlar O, Ondrovicova G, Moskalets T, Skrabana R, Leksa V Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204126 PMC: 11357225. DOI: 10.3390/ph17081021.

Herpesviruses and SARS-CoV-2: Viral Association with Oral Inflammatory Diseases.

Banks J, Capistrano K, Brandini D, Zaidi F, Thakkar P, Rahat R Pathogens. 2024; 13(1).

PMID: 38251365 PMC: 10819702. DOI: 10.3390/pathogens13010058.

Tumor Treating Fields (TTFields) demonstrate antiviral functions , and safety for application to COVID-19 patients in a pilot clinical study.

Abutbul A, Mumblat H, Porat Y, Friedman N, Atari N, Sharabi S Front Microbiol. 2023; 14:1296558.

PMID: 38094629 PMC: 10716356. DOI: 10.3389/fmicb.2023.1296558.

Structural understanding of SARS-CoV-2 virus entry to host cells.

Le K, Kannappan S, Kim T, Lee J, Lee H, Kim K Front Mol Biosci. 2023; 10:1288686.

PMID: 38033388 PMC: 10683510. DOI: 10.3389/fmolb.2023.1288686.

From Emergence to Endemicity: A Comprehensive Review of COVID-19.

Naik R, Avula S, Palleti S, Gummadi J, Ramachandran R, Chandramohan D Cureus. 2023; 15(10):e48046.

PMID: 37916248 PMC: 10617653. DOI: 10.7759/cureus.48046.

References

Oostra M, Hagemeijer M, van Gent M, Bekker C, te Lintelo E, Rottier P . Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning. J Virol. 2008; 82(24):12392-405. PMC: 2593338. DOI: 10.1128/JVI.01219-08. View

Sola I, Almazan F, Zuniga S, Enjuanes L . Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu Rev Virol. 2016; 2(1):265-88. PMC: 6025776. DOI: 10.1146/annurev-virology-100114-055218. View

Te Velthuis A, Arnold J, Cameron C, van den Worm S, Snijder E . The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2009; 38(1):203-14. PMC: 2800238. DOI: 10.1093/nar/gkp904. View

Backer J, Klinkenberg D, Wallinga J . Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020; 25(5). PMC: 7014672. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wu C, Zheng M, Yang Y, Gu X, Yang K, Li M . Furin: A Potential Therapeutic Target for COVID-19. iScience. 2020; 23(10):101642. PMC: 7534598. DOI: 10.1016/j.isci.2020.101642. View

Lai M, Cavanagh D . The molecular biology of coronaviruses. Adv Virus Res. 1997; 48:1-100. PMC: 7130985. View

Moore M, Dorfman T, Li W, Wong S, Li Y, Kuhn J . Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol. 2004; 78(19):10628-35. PMC: 516384. DOI: 10.1128/JVI.78.19.10628-10635.2004. View

Leung G, Hedley A, Ho L, Chau P, Wong I, Thach T . The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004; 141(9):662-73. DOI: 10.7326/0003-4819-141-9-200411020-00006. View

10.

Yang Y, Islam M, Wang J, Li Y, Chen X . Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci. 2020; 16(10):1708-1717. PMC: 7098036. DOI: 10.7150/ijbs.45538. View

11.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

12.

Donaldson E, Graham R, Sims A, Denison M, Baric R . Analysis of murine hepatitis virus strain A59 temperature-sensitive mutant TS-LA6 suggests that nsp10 plays a critical role in polyprotein processing. J Virol. 2007; 81(13):7086-98. PMC: 1933295. DOI: 10.1128/JVI.00049-07. View

13.

Shum K, Tanner J . Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. Chembiochem. 2008; 9(18):3037-45. PMC: 7161993. DOI: 10.1002/cbic.200800491. View

14.

BOS E, Luytjes W, van der Meulen H, Koerten H, Spaan W . The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology. 1996; 218(1):52-60. PMC: 7130547. DOI: 10.1006/viro.1996.0165. View

15.

Khan S, Siddique R, Shereen M, Ali A, Liu J, Bai Q . Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. J Clin Microbiol. 2020; 58(5). PMC: 7180238. DOI: 10.1128/JCM.00187-20. View

16.

Bekerman E, Neveu G, Shulla A, Brannan J, Pu S, Wang S . Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017; 127(4):1338-1352. PMC: 5373883. DOI: 10.1172/JCI89857. View

17.

Ivanov K, Thiel V, Dobbe J, van der Meer Y, Snijder E, Ziebuhr J . Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol. 2004; 78(11):5619-32. PMC: 415832. DOI: 10.1128/JVI.78.11.5619-5632.2004. View

18.

Araki K, Gangappa S, Dillehay D, Rouse B, Larsen C, Ahmed R . Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. J Exp Med. 2010; 207(11):2355-67. PMC: 2964579. DOI: 10.1084/jem.20100124. View

19.

Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley B . Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020; 92(6):602-611. PMC: 7228310. DOI: 10.1002/jmv.25731. View

20.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View